EUVIMEDEUVIMED entdecken
Crossref

GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients

Kelly McKee, Mark Newman

Medical Research Archives · 2025 · 14 (2)

DOI: 10.18103/mra.v14i2.7325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2025. Verfasst von Kelly McKee und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The multiantigen design and viral vector delivery platform of GEO-CM04S1 position this vaccine candidate as a next generation COVID-19 vaccine. Data generated to date indicate that the vaccine induces a durable, broadly specific and broadly functional humoral and cellular immune response to SARS-CoV-2 in both healthy adults and those with compromised immunity. The safety profile, as well as the breadth and magnitude of vaccine-induced T-cell responses supports its use in immunocompromised patients for prevention of severe COVID-19, addressing a critical unmet need. Targeting sequence-conserved structural proteins of this continually evolving pathogen should reduce the burdensome requirement for frequent updating and booster strategies designed to "chase the variant" to maintain efficacy.

Zitieren

APA

McKee, K., & Newman, M. (2025). GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients. Medical Research Archives, 14(2). https://doi.org/10.18103/mra.v14i2.7325

Vancouver

McKee K, Newman M. GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients. Medical Research Archives. 2025;14(2). doi:10.18103/mra.v14i2.7325

BibTeX
@article{McKee2025,
  author = {McKee, Kelly and Newman, Mark},
  title = {GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients},
  journal = {Medical Research Archives},
  year = {2025},
  volume = {14},
  number = {2},
  doi = {10.18103/mra.v14i2.7325}
}
Kostenlos starten →